The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government.
17 Mar 2021
17 Feb 2021
Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.
10 Feb 2021
The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.
05 Feb 2021
Johnson & Johnson’s subsidiary Janssen Biotech has submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) for its investigational single-dose Janssen Covid-19 vaccine candidate.
01 Feb 2021
AstraZeneca has secured a conditional marketing authorisation for its Covid-19 vaccine in the European Union (EU) for active immunisation in individuals aged 18 years and above.
27 Jan 2021
The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.
26 Jan 2021
American pharma giant Merck has announced that it has discontinued the development of its SARS-CoV-2/Covid-19 vaccine candidates V590 and V591, after they performed poorly in phase 1 clinical trials.
20 Jan 2021
Gritstone Oncology, a biotech firm developing vaccines, has announced that it is advancing the development of a second generation vaccine against Covid-19.
18 Jan 2021
Dr. Reddy’s Laboratories has announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
15 Jan 2021
NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, announced completion of a $196M (€160M) Series A funding round.